A randomized comparison of daunorubicin 90 mg/m(2) vs 60 mg/m(2) in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Modifying induction therapy in acute myeloid leukemia (AML) may improve the remission rate and reduce the risk of relapse, thereby improving survival. Escalation of the daunorubicin dose to 90 mg/m(2) has shown benefit for some patient subgroups when compared with a dose of 45 mg/m(2), and has been...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Burnett, Alan K., Russell, Nigel H., Hills, Robert K., Kell, Jonathan, Cavenagh, Jamie, Kjeldsen, Lars, McMullin, Mary-Frances, Cahalin, Paul, Dennis, Mike, Friis, Lone, Thomas, Ian F., Milligan, Don, Clark, Richard E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2015
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4505010/
https://ncbi.nlm.nih.gov/pubmed/25833957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-01-623447
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller